About the Company
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $REGN News
Buy Rating Affirmed for Regeneron on Eylea HD Success and Innovative Obesity Program
Begin your TipRanks Premium journey today. Regeneron (REGN) Company Description: Founded in 1988, Regeneron Pharmaceuticals, Inc. is a New York-based biotechnology company, which discovers, develops, ...
Regeneron (REGN) Gets FDA Nod for Praluent Label Extension
Regeneron Pharmaceuticals, Inc. REGN announced that the FDA extended the approval of the cholesterol drug Praluent’s ...
Regeneron (REGN) to Report Q4 Earnings: What's in the Cards?
Regeneron Pharmaceuticals, Inc.REGN is scheduled to release fourth-quarter 2023 results on Feb 2, before the opening bell. The company has an impressive track record, with an earnings beat in each ...
Regeneron Pharmaceuticals Inc REGN
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Is There An Opportunity With Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) 42% Undervaluation?
Using the 2 Stage Free Cash Flow to Equity, Regeneron Pharmaceuticals fair value estimate ... run through one way of ...
Regeneron Announces FDA Approval Extending Treatment Of Praluent To Children Aged 8
Regeneron Pharmaceuticals, Inc. (REGN) announced the FDA has extended the approval of Praluent as an adjunct to diet and other ...
Regeneron's Praluent injection gets FDA approval to treat kids with genetic form of high cholesterol
Regeneron Pharmaceuticals (NASDAQ:REGN) has received approval from the U.S. Food & Drug Administration (FDA) for its Praluent ...
Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
A replay of the conference call and webcast will be archived on the Company's website for at least 30 days. About Regeneron Pharmaceuticals, Inc. Regeneron is a leading biotechnology company that ...
Regeneron Pharmaceuticals, Inc.: Praluent (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High Cholesterol
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced the U.S. Food & Drug Administration (FDA) has extended the approval of Praluent® (alirocumab) ...
Regeneron Pharmaceuticals Inc REGN
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Regeneron's Praluent injection gets FDA approval to treat kids with genetic form of high cholesterol
Regeneron Pharmaceuticals (NASDAQ:REGN) has received approval from the U.S. Food & Drug Administration (FDA) for its Praluent (alirocumab) injection to treat children with genetic form of high ...
Loading the latest forecasts...